China – For Sinopharm, the efficacy rate of its vaccine is 79%

––1 / 1–

The Chinese laboratory Sinopharm announced on Wednesday that one of its vaccines against Covid-19 was more than 79% effective. The rate is lower than that claimed by its American competitors Pfizer and Moderna.

Sinopharm is the first Chinese pharmacist to report data on the efficacy of a vaccine in preparation. The Chinese authorities have nonetheless started to vaccinate more than a million people with products, which they have not yet formally validated.

In a press release, Sinopharm reported an efficacy rate of 79.43% for this product developed by the CNBG laboratory in Beijing. Pfizer / BioNTech and Moderna advance rates of 95% and 94.1% respectively.

Approval requested

The British company Astrazeneca, associated with the University of Oxford, for its part claimed an effectiveness rate of 70%, but which could reach 100% with two doses.

China, where the new coronavirus appeared a year ago, has put enormous resources into the development of vaccines, which it has promised to make “a global public good”. The country, which has practically stopped the epidemic on its soil, has had to conduct clinical tests in foreign countries, where the circulation of the virus remains intense.

Five Chinese vaccines are currently in phase III clinical trials. Sinopharm did not specifically say whether these trials were completed for this first vaccine. The group said it had filed an application for approval of this first vaccine with the Chinese authorities.

ATS / NXP

Posted today at 07:14-